发明名称 |
BIOLOGICAL MARKERS PREDICTIVE OF ANTI-CANCER RESPONSE TO EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITORS |
摘要 |
The present invention provides diagnostic methods for predicting the effectiveness of treatment of a cancer patient with an EGFR kinase inhibitor. These methods are based on the surprising discovery that the effectiveness of treatment with an EGFR kinase inhibitor is predicted by whether a patient's tumor cells express a high or a low level of the biomarkers vimentin and E-cadherin, such that patients whose tumors express a high level of at least one of the biomarkers vimentin and E-cadherin have a longer overall survival and progression free survival than patients whose tumors express a low level of both vimentin and E-cadherin. The present invention further provides a method for treating tumors or tumor metastases in a patient, comprising the steps of diagnosing a patient's likely responsiveness to an EGFR kinase inhibitor by assessing whether tumor cells express a high level of at least one of the biomarkers vimentin and E-cadherin, and administering to said patient a therapeutically effective amount of an EGFR kinase inhibitor (e.g. erlotinib), particularly when effectiveness of the inhibitor is predicted. |
申请公布号 |
US2012142028(A1) |
申请公布日期 |
2012.06.07 |
申请号 |
US201013264786 |
申请日期 |
2010.04.15 |
申请人 |
RICHARDSON FRANK C.;YOUNG G. DAVID;WOLF JULIE L.;SENNELLO REGINA M.;OSI PHARMACEUTICALS, LLC |
发明人 |
RICHARDSON FRANK C.;YOUNG G. DAVID;WOLF JULIE L.;SENNELLO REGINA M. |
分类号 |
G01N33/566 |
主分类号 |
G01N33/566 |
代理机构 |
|
代理人 |
|
主权项 |
|
地址 |
|